These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
575 related items for PubMed ID: 26010294
1. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia. Garg S, Shanmukhaiah C, Marathe S, Mishra P, Babu Rao V, Ghosh K, Madkaikar M. Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294 [Abstract] [Full Text] [Related]
2. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells. Mohammadi S, Ghaffari SH, Shaiegan M, Zarif MN, Nikbakht M, Akbari Birgani S, Alimoghadam K, Ghavamzadeh A. Life Sci; 2016 May 01; 152():190-8. PubMed ID: 27063991 [Abstract] [Full Text] [Related]
3. Antigen expression on a putative leukemic stem cell population and AML blast. Garg S, Ghosh K, Madkaikar M. Int J Hematol; 2016 May 01; 103(5):567-71. PubMed ID: 26910244 [Abstract] [Full Text] [Related]
4. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo. Yang J, Ikezoe T, Nishioka C, Nobumoto A, Yokoyama A. Int J Cancer; 2013 Oct 15; 133(8):1967-81. PubMed ID: 23564444 [Abstract] [Full Text] [Related]
5. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. Cook AM, Li L, Ho Y, Lin A, Li L, Stein A, Forman S, Perrotti D, Jove R, Bhatia R. Blood; 2014 May 01; 123(18):2826-37. PubMed ID: 24668492 [Abstract] [Full Text] [Related]
6. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M. Cytometry A; 2015 Apr 01; 87(4):346-56. PubMed ID: 25598437 [Abstract] [Full Text] [Related]
8. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ. Leukemia; 2007 Aug 01; 21(8):1700-7. PubMed ID: 17525725 [Abstract] [Full Text] [Related]
16. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells. Nishioka C, Ikezoe T, Furihata M, Yang J, Serada S, Naka T, Nobumoto A, Kataoka S, Tsuda M, Udaka K, Yokoyama A. Int J Cancer; 2013 May 01; 132(9):2006-19. PubMed ID: 23055153 [Abstract] [Full Text] [Related]
17. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway. Zhang Y, Chen HX, Zhou SY, Wang SX, Zheng K, Xu DD, Liu YT, Wang XY, Wang X, Yan HZ, Zhang L, Liu QY, Chen WQ, Wang YF. Mol Cancer; 2015 Mar 07; 14():56. PubMed ID: 25890196 [Abstract] [Full Text] [Related]